vVARDIS Holding AG
vVARDIS Holding AG, a dental medtech company, develops and provides non-invasive cavity treatment products in Switzerland and the United States. The company offers the Curodont platform, including Curodont Repair, a biomimetic system to arrest and reverse early caries through enamel regeneration; Curodont Protect, a remineralising tooth gel containing the biomimetic Oligo-Peptide 103 technology; and Enamel Serum, enriched with peptides and hydroxyapatite, which delivers calcium and phosphate ions to care for the enamel. The company was incorporated in 2020 and is based in Zug, Switzerland. vVARDIS Holding AG operates as a subsidiary of VVARDIS Investment Holding AG.
vVARDIS (NYSE: VVVV) began trading on the NYSE, offering a drill-free treatment for early tooth decay. Its product, Curodont Repair Fluoride Plus, uses peptide technology to remineralize enamel. The company aims to address a global issue, with 2.5 billion people affected by untreated tooth decay.
Abivardi Bronner Haleh (Co-CEO, Co-Founder & Co-Chair) sold (to issuer) 14,388,879 indirectly-held shares of vVARDIS Holding AG (VVVV) on 2026-11-13.
Abivardi Signer Golnar (Co-CEO, Co-Founder & Co-Chair) sold (to issuer) 14,388,879 indirectly-held shares of vVARDIS Holding AG (VVVV) on 2026-11-13.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning VVVV (vVARDIS Holding AG). Coverage has skewed bullish: 8 bullish, 1 neutral, and 0 bearish.
Recent VVVV coverage spans insider activity, corporate actions and financial news.
In the last 30 days, VVVV insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales. The most active reporter was Abivardi Signer Golnar, Co-CEO, Co-Founder & Co-Chair, with 1 filing.
First‑day trading may see buying pressure as investors assess the novel dental‑care technology.
Abivardi Bronner Haleh (Co-CEO, Co-Founder & Co-Chair) sold (to issuer) 14,388,879 indirectly-held shares of vVARDIS Holding AG (VVVV) on 2026-11-13.
Abivardi Signer Golnar (Co-CEO, Co-Founder & Co-Chair) sold (to issuer) 14,388,879 indirectly-held shares of vVARDIS Holding AG (VVVV) on 2026-11-13.
First‑day pricing provides a baseline for the new public company.
The IPO pricing and capital raise provide immediate market visibility and potential demand for the new listing.
AlphAI scores every news story that mentions VVVV with an AI model for sentiment and relevance, and aggregates insider trades from vVARDIS Holding AG's SEC EDGAR Form 4 filings. Figures refresh continuously.
vVARDIS (NYSE: VVVV) began trading on the NYSE, offering a drill-free treatment for early tooth decay. Its product, Curodont Repair Fluoride Plus, uses peptide technology to remineralize enamel. The company aims to address a global issue, with 2.5 billion people affected by untreated tooth decay.
Abivardi Bronner Haleh (Co-CEO, Co-Founder & Co-Chair) sold (to issuer) 14,388,879 indirectly-held shares of vVARDIS Holding AG (VVVV) on 2026-11-13.
Abivardi Signer Golnar (Co-CEO, Co-Founder & Co-Chair) sold (to issuer) 14,388,879 indirectly-held shares of vVARDIS Holding AG (VVVV) on 2026-11-13.
U.S. indices ended the week higher despite a Friday decline, with the S&P 500 up 2.15%, Nasdaq up 1.92%, and Dow up 1.83%. Eli Lilly (LLY) announced a $3.5B facility for obesity drugs. vVardis (VVVV) priced its IPO at $18 per share. NVIDIA (NVDA) faces a securities class action. Caterpillar (CAT) is under investigation for inventory and cost disclosures. Bank of America (BAC) is involved in a securities fraud lawsuit.
vVardis (VVVV) raised $175M in its IPO, pricing 9.72M shares at $18 each. The dental health firm will list on the NYSE. VAST Data secured $10B in commitments for its AI OS. Kraft Heinz (KHC) shares rose 0.9% on Thursday. Both vVardis and VAST Data's leaders will join NYSE Live.
